We aim to supply brain tissue and psychometric data for research to the neuroscience community, exercising responsible stewardship for the brain tissue and maximizing the potential benefit of this precious resource.
Please contact BDR if you wish to discuss a potential application informally and to request a BDR Tissue or Data Request Form.
As part of our favourable opinion from our Ethics Committee we are able to offer UK-based studies using tissue and associated data obtained via Brains for Dementia Research ‘generic ethical approval’. This will, in most cases, enable studies to proceed without researchers being required to obtain their own ethical approval. Researchers from outside the UK will need to provide evidence of Institutional Review Body approval.
In order to approve a project we require sufficient information about the proposed research that will enable assessment of the validity, methodology, peer review process, funding and contribution the proposed work will make to understanding and developing treatments for dementia. We are very happy to consider pilot studies and to assist first time users. No distinction is made between applications from academic groups and those from commercial organisations.
All Brains for Dementia Research tissue is listed on the UK Brain Banks Network database however you may find it useful to have a preliminary discussion of requirements either by contacting BDR Coordinating Centre (contact BDR) or one of the Brain Banks.
“Dementia, the progressive loss of intellectual and social abilities, is one of the biggest curses of this time. In my laboratory we are working very hard to understand what goes wrong in the brain of patients. We want to find a cure and want to learn how we can prevent this disorder in future generations. My international group of young researchers and I need brain material for our work, from healthy people and those with dementia. It is very difficult to obtain such material and BDR has been instrumental for our studies. We are proud that we have recently published some new insights based on the work with the BDR brains that will help us to make safer medicines in the future.”
Recent publications which have benefitted from BDR support:
- Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer’s disease and track disease progression and cognitive decline. DJ Koss et al, Acta Neuropathologica (2016).
- Vascular Cognitive Impairment Neuropathology Guidelines (VCING) – the contribution of cerebrovascular pathology to cognitive impairment. O Skrobot et al., Brain, 2016.
- Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology. A Olmos-Alonso et al., Brain, 2016.
- DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study. Trinh J et al, Lancet Neurol (2016).
- Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Kun-Rodrigues C et al, Neurobiol Aging (2016).
- RT-QuIC for the detection of alpha-synuclein in the CSF of patients with alpha-synucleinopathies. Fairfoul G et al, Ann Clin Transl Neurol (2016).
- Regional levels of physiological α-synuclein are directly associated with Lewy body pathology. Erskine et al, Acta Neuropathologica (2018).
- Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. E Bereczki et al, Brain (2018).